GlaxoSmithKline (GSKN) Financial Statements
GlaxoSmithKline Financial Overview
GlaxoSmithKline's market cap is currently $1.87T. The company's EPS TTM is $2.16; its P/E ratio is 17.18; and it has a dividend yield of 3.38%. GlaxoSmithKline is estimated to report earnings on February 3, 2027, and the estimated EPS forecast is $13.88. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 32.67B | $ 31.38B | $ 30.33B | $ 29.32B | $ 24.70B |
| Gross Profit | $ 23.65B | $ 22.33B | $ 21.76B | $ 19.77B | $ 16.53B |
| Operating Income | $ 8.34B | $ 4.02B | $ 6.75B | $ 6.43B | $ 4.36B |
| EBITDA | $ 10.40B | $ 6.67B | $ 9.08B | $ 8.60B | $ 6.49B |
| Net Income | $ 5.72B | $ 2.58B | $ 4.93B | $ 14.96B | $ 4.38B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 3.40B | $ 3.71B | $ 6.61B | $ 7.88B | $ 5.87B |
| Total Assets | $ 61.01B | $ 59.46B | $ 75.22B | $ 60.15B | $ 107.14B |
| Total Debt | $ 17.69B | $ 16.99B | $ 22.97B | $ 20.99B | $ 32.74B |
| Net Debt | $ 14.30B | $ 13.29B | $ 19.23B | $ 17.26B | $ 26.95B |
| Total Liabilities | $ 45.02B | $ 46.38B | $ 58.91B | $ 50.05B | $ 78.23B |
| Stockholders' Equity | $ 16.35B | $ 13.67B | $ 17.01B | $ 10.60B | $ 20.39B |
| Cash Flow | |||||
| Free Cash Flow | $ 5.82B | $ 3.57B | $ 6.26B | $ 6.75B | $ 5.30B |
| Operating Cash Flow | $ 7.14B | $ 6.55B | $ 7.89B | $ 8.16B | $ 7.95B |
| Investing Cash Flow | $ -5.72B | $ -1.23B | $ -2.40B | $ -10.88B | $ -1.78B |
| Financing Cash Flow | $ -1.59B | $ -4.73B | $ -6.07B | $ 2.05B | $ -7.59B |
Currency in GBP